SynthesisBMC cancer2019
The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis.
Lihu Gu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
51 papers cite it
this paperpooled itcites it